cancerpatients
-
GU CANCERS
Nano-Particles Show Breakthrough Potential in Fighting Prostate Cancer
A preclinical study led by researchers at Weill Cornell Medicine and the Cornell Duffield College of Engineering has revealed…
Read More » -
Cancer
AROUND THE CORNER:Top Developments in Genitourinary Cancer Therapeutics
Enfortumab Vedotin Plus Pembrolizumab Reshapes the Perioperative MIBC Paradigm Representative trial: KEYNOTE-B15/EV-304 — Phase 3 results presented at ASCO GU…
Read More » -
Cancer
Most Clinically Significant Kidney Cancer Presentations from ASCO 2026
Primary data drawn from ASCO 2026 presentations, JCO supplement abstracts, press releases, and peer-reviewed commentary. Abstract 1 — LBA418 LITESPARK-022:…
Read More » -
Cancer
The Architecture of a Cure: Where Renal Cell Carcinoma Research Stands in 2026
Thomas E. Hutson, DO, PharmD, FACP EDITORIAL NOTE | Editor-in-Chief, Kidney Cancer Journal There is a particular kind…
Read More » -
ASCO
ASCO 2026 Annual Meeting: Kidney Cancer: Clinical and Research Highlights
[ A Summary Report from Kidney Cancer Journal ] Chicago, Illinois | May 29 – June 2, 2026 | Kidney…
Read More » -
Conferences
ESMO’22 Recommended Abstracts in RENAL CANCERS
Robert A. Figlin, MD, Editor-in- Chief of the Kidney Cancer Journal. These recommended abstracts from ESMO 2022 Annual meeting have been…
Read More » -
Cancer
Gene activity Can Provide Clues for Risk of Kidney Cancer Spreading
OCTOBER 17, 2022 – 4 MINUTES READ The activity of four specific genes in the cancer cells seems to…
Read More » -
Cancer
A 20-year retrospective: How Kidney Cancer Journal Reflected on Advances in The Therapeutic Strategies
Robert A Figlin, MD, FACP1 , Senthil Pazhanisamy, PhD2 1. Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Health System, Los Angeles…
Read More » -
Conferences
2022 ESMO: Promise and Pitfalls of Adjuvant Immunotherapy
ESMO’22 Special Robert A. Figlin, MD, FACS Cedars Cinai Cancer Center, Los Angeles, CA Correspondence: RAF There was never a…
Read More » -
Kidney Cancer
Optimal Duration of Therapy in Metastatic RCC: Exploring Treatment-Free Survival with Checkpoint Inhibitors
Grayce N. Selig, MD1 Christopher J. Hoimes, DO,2 Joe Bible, PhD,3 Daniel J. George, MD,2 Michael R. Harrison, MD2 1. Duke University Medical Center…
Read More »
